[Diagnosis of sarcopenic obesity could add extra clinical implications to severe obesity].

Sarcopenic obesity was present in 22.6% of patients with severe obesity who were candidates for bariatric surgery.

• 28 out of 124 patients met criteria for sarcopenic obesity (SO)
• Diagnosis was made according to ESPEN/EASO criteria
• Study population had BMI >40 kg/m² or BMI 35-40 kg/m² with comorbidities
• Patients were aged 18 to 60 years

Patients with sarcopenic obesity had significantly greater anthropometric measurements compared to those without SO.

• Patients with SO had higher weight, BMI, waist circumference, and calf circumference (P<.05)
• Body composition was evaluated by DXA measuring fat mass and appendicular lean mass
• Muscle strength was assessed by hand grip dynamometry

Patients with sarcopenic obesity had a higher prevalence of cardiometabolic comorbidities.

• Higher prevalence of arterial hypertension (AHT), type 2 diabetes mellitus (DM2), and hypertriglyceridemia in SO patients (P<.05)
• There was a tendency toward more complications such as obstructive sleep apnea (OSA) and cholelithiasis, though not reaching statistical significance
• Findings suggest a worse cardiometabolic profile associated with SO diagnosis

Patients with sarcopenic obesity demonstrated worse physical performance and higher risk of falls.

• Patients with SO showed slower Timed-Up-and-Go (TUG) test times (P<.05)
• Patients with SO had a higher risk of falls (P<.05)
• Physical performance was evaluated using the Timed-Up-and-Go test

There were no significant differences in quality of life, drug consumption, or health resource utilization between patients with and without sarcopenic obesity.

• Quality of life was measured using the EuroQol-5D instrument
• No significant differences were found in drug consumption
• No significant differences were found in use of health resources between SO and non-SO patients